Pair page
Tirzepatide with VK2735
Mechanism-tag overlap and published literature for Tirzepatide and VK2735, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
dual-gip-glp-1-receptor-agonist
viking-therapeutics
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Tirzepatide and VK2735 have published these mechanism-level observations. Not a co-administration recommendation.
Not a stack — direct competitor. Same receptor class; should never be co-administered. Included here for comparison context only. Patients may transition between them based on access, insurance, or tolerability in clinical contexts.
Quick facts
Tirzepatide
VK2735
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2022 | Tirzepatide | Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11)… PMID 36152639 | human trial, Phase 3 |
| 2021 | Tirzepatide | Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al.; SURPASS-1 Investigators. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet.… PMID 34186022 | human trial, Phase 3 |
| 2021 | Tirzepatide | Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group,… PMID 34370970 | human trial, Phase 3 |
| 2021 | Tirzepatide | Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 202… PMID 34672967 | human trial, Phase 3 |
| 2025 | Tirzepatide | Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al.; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PMID: 39536238. PMID 39536238 | human trial |
| 2024 | Tirzepatide | Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. PMID 38078870 | human trial |
| 2024 | Tirzepatide | Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. PMID 38912654 | human trial |
| 2023 | Tirzepatide | Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275. PMID 37385275 | human trial |
| 2022 | Tirzepatide | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PMID 35658024 | human trial |
| 2022 | Tirzepatide | Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PMID: 3513… PMID 35133415 | human trial |
| 2021 | Tirzepatide | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| 2018 | Tirzepatide | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
| 2024 | VK2735 | Viking Therapeutics. Corporate presentations and SEC filings, 2024–2026, detailing VK2735 Phase 2 data, oral formulation development, and anticipated Phase 3 timeline. | human trial, Phase 3 |
| 2024 | VK2735 | Viking Therapeutics. VK2735 Phase 2 (VENTURE) topline results: 13-week weight-loss data in adults with obesity. Press release and investor presentations, 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Bays HE, Kelly AS, Aronne LJ, et al. Weekly subcutaneous VK2735 for weight management in adults with obesity — Phase 2 VENTURE trial. ObesityWeek 2024 / Obesity (Silver Spring). 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Viking Therapeutics. Phase 1 and Phase 2 oral VK2735 program: pharmacokinetics and early weight-loss signal. 2024–2025 communications. | human trial, Phase 2 |
| 2023 | VK2735 | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. PMID 37366315 | human trial, Phase 2 |
| — | VK2735 | ClinicalTrials.gov. A Study of VK2735 in Participants With Obesity (VENTURE). NCT05946356. | human trial |
| 2022 | VK2735 | Viking Therapeutics. Phase 1 pharmacokinetics, safety, and tolerability of subcutaneous VK2735 in healthy and obese volunteers. 2022–2023. | human trial, Phase 1 |
| 2023 | VK2735 | Wharton S, Astrup A, Endahl L, Lean MEJ, Satylganova A, Skovgaard D, Wadden TA. Oral semaglutide for the treatment of obesity. Lancet. 2023;402(10403):653-656. (Oral semaglutide class context.) | human study |
| 2025 | VK2735 | World Anti-Doping Agency. 2025 WADA Prohibited List. WADA, 2025. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Tirzepatide and VK2735 been studied together?
Researchers have published mechanistic-level co-administration discussion of Tirzepatide and VK2735. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Tirzepatide and VK2735 share?
Tirzepatide and VK2735 share these mechanism tags on their Kalios profiles: dual-gip-glp-1-receptor-agonist. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Tirzepatide and VK2735?
Tirzepatide: Approved (T2D 2022, obesity 2023, OSA 2024). VK2735: Investigational (Phase 2). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Tirzepatide and VK2735?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Tirzepatide profile and the VK2735 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026